MetaVia (MTVA) Cash & Equivalents (2015 - 2026)
MetaVia's (MTVA) quarterly Cash & Equivalents came in at $10.3 million in Q4 2025, down 35.69% YoY from $16.0 million in Q4 2024, and down 27.97% on a QoQ basis from $14.3 million in Q3 2025.
MetaVia (MTVA) Cash & Equivalents (2015 - 2026) Analysis & Trends
MetaVia (MTVA) has 11 years of Cash & Equivalents data on file, last reported at $10.3 million in Q4 2025.
- Quarterly Cash & Equivalents fell 35.69% year-over-year to $10.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $10.3 million (down 35.69% YoY) and the FY2025 annual result came in at $10.3 million, down 35.69% from the prior year.
- Cash & Equivalents declined to $10.3 million in Q4 2025, from $14.3 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $33.4 million in Q4 2022 to a low of $6.4 million in Q3 2022.
- A 5-year average of $17.4 million and a median of $16.0 million in 2024 frame the typical range for Cash & Equivalents.
- Annual changes were most pronounced in 2021 — Cash & Equivalents surged 86800.0% — and 2024, when it tumbled 48.11%.
- Tracing MTVA's Cash & Equivalents over 5 years: stood at $16.4 million in 2021, then jumped by 103.6% to $33.4 million in 2022, then plunged by 32.76% to $22.4 million in 2023, then fell by 28.61% to $16.0 million in 2024, then sank by 35.69% to $10.3 million in 2025.
- The last three Cash & Equivalents figures came in at $10.3 million (Q4 2025), $14.3 million (Q3 2025), and $17.6 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 3.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.72 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.71 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 8.93 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 544.80 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 811.99 Mn |
| 10 | MetaVia | 8.72 Mn | -3.92 Mn | - | 12.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.63 Mn |
| Dec 31, 2025 | 10.30 Mn |
| Sep 30, 2025 | 14.30 Mn |
| Jun 30, 2025 | 17.60 Mn |
| Mar 31, 2025 | 11.19 Mn |
| Dec 31, 2024 | 16.02 Mn |
| Sep 30, 2024 | 21.70 Mn |
| Jun 30, 2024 | 27.93 Mn |
| Mar 31, 2024 | 15.99 Mn |
| Dec 31, 2023 | 22.44 Mn |
| Sep 30, 2023 | 25.84 Mn |
| Jun 30, 2023 | 28.69 Mn |
| Mar 31, 2023 | 30.81 Mn |
| Dec 31, 2022 | 33.36 Mn |
| Sep 30, 2022 | 6.40 Mn |
| Jun 30, 2022 | 8.85 Mn |
| Mar 31, 2022 | 11.60 Mn |
| Dec 31, 2021 | 16.39 Mn |
| Sep 30, 2021 | 7.00 Mn |
| Jun 30, 2021 | 9.50 Mn |